Innovative chip-based device for the screening of Parkinson's disease medications
There is a growing interest in developing and investing in organ-on-a-chip devices from basic researchers and biotech and pharmaceutical companies. The lab-on-a-chip devices offer highly accessible systems for testing hypothesis-driven research ideas and screening of potential therapeutic compounds. Importantly, chip-based devices allow ultra-low-cost test solutions for medications. The goal of the EU-funded NMJ project is to develop a neuromuscular-junction-on-a-chip device tailored as α-synuclein-induced Parkinson's disease model. The objective is to introduce this chip-based device for testing Parkinson's disease medications proposed by Novartis and GlaxoSmithKline. The French microfluidic innovation centre Elvesys in Paris will provide expert support to the project.
Fields of science
- natural sciencesphysical sciencesclassical mechanicsfluid mechanicsmicrofluidics
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- engineering and technologyother engineering and technologiesmicrotechnologylab on a chip
- medical and health sciencesbasic medicineneurologyparkinson
- medical and health sciencesmedical biotechnologyimplants